Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- PHAR
- Price
- 19.93
- Stock movement up
- +2.01 (11.22%)
- Company name
- Pharming Group NV
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.39B
- Ent value
- 1.45B
- Price/Sales
- 3.83
- Price/Book
- 6.16
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 3634.82
- Forward P/E
- 313.86
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- 108.69%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-01-22
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
PHAR does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 3634.82 |
| Price to OCF | 27.06 |
| Price to FCF | 27.39 |
| Price to EBITDA | 47.72 |
| EV to EBITDA | 49.97 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3.83 |
| Price to Book | 6.16 |
| EV to Sales | 4.01 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 69.67M |
| EPS (TTM) | 0.01 |
| FCF per share (TTM) | 0.76 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 362.27M |
| Gross profit (TTM) | 325.69M |
| Operating income (TTM) | 33.32M |
| Net income (TTM) | 382.00K |
| EPS (TTM) | 0.01 |
| EPS (1y forward) | 0.06 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 89.90% |
| Operating margin (TTM) | 9.20% |
| Profit margin (TTM) | 0.11% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 112.75M |
| Net receivables | 37.14M |
| Total current assets | 236.46M |
| Goodwill | 0.00 |
| Intangible assets | 114.93M |
| Property, plant and equipment | 24.99M |
| Total assets | 403.57M |
| Accounts payable | 66.63M |
| Short/Current long term debt | 111.52M |
| Total current liabilities | 74.89M |
| Total liabilities | 178.15M |
| Shareholder's equity | 225.42M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 51.32M |
| Capital expenditures (TTM) | 620.69K |
| Free cash flow (TTM) | 50.70M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 0.17% |
| Return on Assets | 0.09% |
| Return on Invested Capital | 0.12% |
| Cash Return on Invested Capital | 15.51% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 19.53 |
| Daily high | 20.09 |
| Daily low | 19.32 |
| Daily Volume | 37K |
| All-time high | 19.93 |
| 1y analyst estimate | 31.00 |
| Beta | 0.18 |
| EPS (TTM) | 0.01 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 12 Mar 2026 |
Downside potential
Loading...
Downside potential data
| PHAR | S&P500 | |
| Current price drop from All-time high | -4.58% | -2.53% |
| Highest price drop | -54.01% | -19.00% |
| Date of highest drop | 29 Nov 2024 | 8 Apr 2025 |
| Avg drop from high | -30.29% | -2.49% |
| Avg time to new high | 36 days | 6 days |
| Max time to new high | 246 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.39B
Marketcap category
Small-cap
Description
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. It has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Employees
404
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page